Background: Painful breast carcinoma metastases in bone are a common manifestation of malignant disease. Eradication of these tumors can be evasive, and as a result, skeletal morbidity increases with disease progression. Experimental Design: The treatment potential of cytosine deaminase (CD) gene therapy combined with radiation treatment was evaluated in vitro and in vivo using a 4T1 murine breast carcinoma model. 4T1 carcinoma cells were transduced with a fusion gene encoding the extracellular and transmembrane domains of the human nerve growth factor receptor and the cytoplasmic portion of the yeast CD gene (NGFR-CD y ). Results and Conclusions: CD-expressing tumor cells (4TCD y ) were highly sensitive to treatment by 5-fluorocytosine prodrug (P < 0.0001). 5-Fluorocytosine treatment of 4TCD y , but not 4T1 cells, enhanced the effects of radiation in vitro (P < 0.0001). 5-Fluorocytosine prodrug treatment also increased the therapeutic potential of radiation in vivo. Mice with 4TCD y intrafemoral tumors showed increased effectiveness of radiation based on improved reductions in tumor size, reductions in tumorigenic osteolysis, and a decrease in skeletal fractures (P < 0.01).Enzyme/prodrug gene therapy involves expression of a nonmammalian enzyme that converts a nontoxic prodrug to a cytotoxic agent at sites of tumor. The cytosine deaminase (CD)/5-fluorocytosine (5-FC) enzyme/prodrug system converts 5-FC to the highly cytotoxic compound 5-fluorouracil (5-FU) and is a promising therapeutic approach for the treatment of tumors because of its potential for sensitizing tumor cells to radiation treatment. Deamination of 5-FC by CD-expressing tumor cells produces 5-FU. Intracellular 5-FU is then converted to the active metabolites 5-fluoro-2-dUMP (FdUMP) or 5-fluoro-2-dUTP. 5-FU can passively diffuse across the cell membrane and enter adjacent cells where intracellular conversion of 5-FU to FdUMP is done by thymidine kinase. FdUMP inhibits cellular DNA synthesis by binding to and inhibiting thymidylate synthase (1, 2). Although 5-FU has both DNA-directed and RNA-directed effects, its radiationenhancing effects result from DNA-directed mechanisms (3). These include lethal influences on radioresistant S-phase cells and reduction in DNA repair after radiation-induced DNA injury (1).Because 5-FU has been shown to enhance the effect of radiation on tumor cells, the CD/5-FC enzyme/prodrug system is attractive as an adjuvant for treating tumors that will receive radiation treatment (4). The CD/5-FC enzyme/prodrug system has been used in conjunction with radiation treatment in experimental animal models and clinical trials for treating softtissue cancers. Soft-tissue cancers studied with this concomitant therapy include colon, nasopharyngeal, prostate, esophageal, and breast cancers, malignant gliomas and sarcomas, and epidermoid carcinoma (4 -10). Treatment of soft-tissue cancers in experimental models has involved delivery of the CD gene via tumor cell transduction or delivery of adenovirus containing the CD gene fo...